These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2938736)

  • 21. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
    Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
    Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
    Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
    Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
    Miller SD; Butler LD; Cleveland RP; Moorhead JW; Claman HN; Chiller JC
    Cell Immunol; 1983 Dec; 82(2):378-93. PubMed ID: 6197193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY; Howard JG; Hale C
    J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of L3T4 antigen in the activation of various functions of Lyt-1+2- T cells against vaccinia virus.
    Aoyama A; Yoshioka T; Sato S; Mizushima Y; Ogata M; Ueda S; Kato S; Fujiwara H; Hamaoka T
    Microbiol Immunol; 1986; 30(8):799-810. PubMed ID: 2946922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
    Fuyama S; Komatsu H; Arai S
    Cell Immunol; 1991 Oct; 137(1):200-15. PubMed ID: 1679379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunopharmacological actions of an extract isolated from inflamed skin of rabbits inoculated with vaccinia virus (neurotropin); enhancing effect on delayed type hypersensitivity response through the induction of Lyt-1+2- T cells.
    Yoshii H; Suehiro S; Watanabe K; Yanagihara Y
    Int J Immunopharmacol; 1987; 9(4):443-51. PubMed ID: 2957331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
    Sato S; Fukuzawa M; Nakajima H; Ogata M; Kosugi A; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Nov; 76(11):1099-106. PubMed ID: 2935516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
    J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses.
    Miller SD; Butler LD
    J Immunol; 1983 Jul; 131(1):77-85. PubMed ID: 6190929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
    Sato S; Fujiwara H; Kosugi A; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness.
    Mizuochi T; Munitz TI; McCarthy SA; Andrysiak PM; Kung J; Gress RE; Singer A
    J Immunol; 1986 Nov; 137(9):2740-7. PubMed ID: 2944960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of tumor-bearing mice utilizing virus help.
    Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
    Cancer Immunol Immunother; 1988; 27(3):223-7. PubMed ID: 3263207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K; Hamaoka T; Tominaga A; Kanamasa Y
    J Immunol; 1980 Dec; 125(6):2367-73. PubMed ID: 6776192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.
    Sano S; Izumi Y; Sugihara S; Nakajima H; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(2):105-10. PubMed ID: 3499223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.